What is the appropriate management of angina pectoris?

Management of Angina Pectoris

All patients with stable angina pectoris should receive aspirin 75 mg daily, statin therapy, and sublingual nitroglycerin for acute symptom relief, with beta-blockers as first-line regular anti-anginal therapy unless contraindicated. 1, 2

Medications to Prevent MI and Death (Prognostic Therapy)

These medications improve survival and must be prescribed to all patients:

• Aspirin 75-300 mg daily (Level A evidence) - reduces subsequent vascular events 3

  • If aspirin is absolutely contraindicated (active GI bleeding, true allergy), use clopidogrel instead 2

• Statin therapy for all patients (Level A evidence) - regardless of baseline cholesterol 1, 2

  • High-dose statins for high-risk patients (>2% annual CV mortality) 1

• ACE inhibitors (Level A evidence):

  • Mandatory if: hypertension, heart failure, LV dysfunction, prior MI with LV dysfunction, or diabetes 1, 2
  • Should be considered in all patients with proven coronary disease, especially those at very high cardiovascular risk 1, 4

• Beta-blockers (Level A evidence):

  • Mandatory post-MI or with heart failure - reduces mortality by 24-30% 1, 2
  • Recommended even without prior MI (Level B evidence) 2

• Low-dose colchicine 0.5 mg daily should be considered to reduce MI, stroke, and need for revascularization 4

Medications for Symptom Relief (Anti-Anginal Therapy)

Acute Relief

• Sublingual nitroglycerin as needed for pain and before activities that trigger angina 3
  • If sublingual fails, consider buccal preparations 3
  • Critical warning: Angina unresponsive to nitroglycerin suggests possible MI 1

Regular Symptomatic Treatment

First-line: Beta-blockers 3

• Start here unless contraindicated
• Use the cheapest preparation the patient tolerates that controls symptoms
• Never stop abruptly - must taper over 4 weeks to avoid rebound 3

If beta-blockers contraindicated or not tolerated:

• Long-acting calcium channel blockers (dihydropyridines like amlodipine OR non-dihydropyridines like verapamil/diltiazem) 2
• OR long-acting nitrates 2
• Avoid short-acting dihydropyridines - they increase adverse cardiac events 2

If monotherapy inadequate:

• Add long-acting calcium channel blocker OR long-acting nitrate to beta-blocker 2
• Can combine beta-blocker with long-acting calcium channel blocker 1

Important nitrate consideration:

• All nitrates (oral and patches) must be used with nitrate-free intervals to avoid tolerance 3
• Patches should be ≥10 mg dosage 3

Second-line agents when first-line combinations fail:

• Ivabradine, nicorandil, ranolazine, or trimetazidine may be added 4
• Ranolazine has the strongest recent evidence among these 5

When to Escalate Beyond Two Drugs

If symptoms uncontrolled on maximal doses of two drugs:

• Evidence-based options are very limited 3
• Refer to cardiology for angiography rather than adding a third drug 3
• If third drug is tried, monitor effect closely and stop if ineffective 3

Essential Lifestyle Modifications

• Smoking cessation (Level A evidence) - advise all smokers to stop; nicotine patches are safe in CAD 3
• Blood pressure control - measure in all patients; treat per hypertension guidelines 3
• Cholesterol management - measure in all patients 3
• Weight reduction if BMI elevated 3
• Exercise therapy - improves functional capacity 6

When to Refer to Cardiology

Refer all patients with:

• Clinically certain angina to identify those who would benefit from prognostic investigation 3
• Uncertain diagnosis for clarification 3
• Symptoms uncontrolled despite optimal medical therapy 3
• Uncontrolled symptoms on full doses of two drugs - refer for angiography, not exercise testing 3

Revascularization Considerations

• PCI or CABG improves angina-related health status 4
• CABG superior to PCI for multivessel disease, especially with diabetes and higher coronary complexity 4
• CABG provides survival benefit for left main disease and three-vessel disease, particularly with LV dysfunction 4
• Recent evidence (ISCHEMIA trial) shows initial conservative medical management is generally preferred, but revascularization reduces spontaneous MI and improves angina symptoms more than medical therapy alone 4

Common Pitfalls to Avoid

• Do not use immediate-release or short-acting dihydropyridine calcium antagonists - they increase adverse events 2
• Do not use dipyridamole or chelation therapy - no benefit for preventing MI/death 2, 7
• Avoid nitrate tolerance by ensuring nitrate-free intervals 1, 3
• Never abruptly discontinue beta-blockers - taper over 4 weeks 3
• Do not add third anti-anginal without specialist input - refer instead 3